Arch Biopartners Inc. ("Arch" or the "Company")

(CNSX:ACH)(OTCBB:FOIFF) today announced that the National Research

Council of Canada - Industrial Research Assistance Program (NRC-IRAP)

has approved funding up to $107,000 to assist Arch in the development

of diagnostic imaging applications for its brain tumour initiating

cell ("BTIC") targeting technology.

Arch Cancer Therapeutics (ACT), a subsidiary of the Company, is

currently working with NRC-IRAP to develop prototype BTIC diagnostic

imaging agents for use in magnetic resonance imaging ("MRI").

It is anticipated that this assistance from NRC-IRAP will allow Arch

to complete prototype development of its BTIC-targeting technology for

use in MRI within the next 12 months.

BTICs are a cancer stem cell population that represent a significant

disease reservoir believed to play an important role in the formation

and recurrence of malignant glioma in humans. BTICs are not detected

by current medical diagnostic imaging technologies.

About Arch Cancer Therapeutics

ACT is an Alberta corporation wholly owned by Arch Biopartners. ACT's

objective is to develop non-invasive diagnostic and therapeutic

molecules for brain cancer. These molecules are specialized peptides

proprietary to ACT that identify and target brain tumor initiating

cells ("BTIC") and invasive brain cancer cells that are not normally

seen using current state of the art diagnostic imaging techniques.

About Arch Biopartners

Arch Biopartners is a portfolio based biotechnology company

established to develop new products and technology for sale to

pharmaceutical and industrial companies.

For more information on the Company, please consult the other public

documents filed on SEDAR at

The Company's website address is:

Forward-Looking Statements

All statements, other than statements of historical fact, in this news

release are forward looking statements that involve various risks and

uncertainties, including, without limitation, statements regarding the

future plans and objectives of the Company. There can be no assurance

that such statements will prove to be accurate. Actual results and

future events could differ materially from those anticipated in such

statements. These and all subsequent written and oral forward-looking

statements are based on the estimates and opinions of management on

the dates they are made and are expressly qualified in their entirety

by this notice. The Company assumes no obligation to update

forward-looking statements should circumstances or management's

estimates or opinions change.

The CNSX has not reviewed and does not accept responsibility for the

adequacy of this release.